<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33074248</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-8238</ISSN><JournalIssue CitedMedium="Internet"><Volume>130</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Stathmin-2: adding another piece to the puzzle of TDP-43 proteinopathies and neurodegeneration.</ArticleTitle><Pagination><StartPage>5677</StartPage><EndPage>5680</EndPage><MedlinePgn>5677-5680</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI142854</ELocationID><ELocationID EIdType="pii" ValidYN="Y">142854</ELocationID><Abstract><AbstractText>Cytoplasmic aggregated proteins are a common neuropathological feature of neurodegenerative diseases. Cytoplasmic mislocalization and aggregation of TAR-DNA binding protein 43 (TDP-43) is found in the majority of patients with amyotrophic lateral sclerosis (ALS) and in approximately 50% of patients dying of frontotemporal lobar degeneration (FTLD). In this issue of the JCI, Prudencio, Humphrey, Pickles, and colleagues investigated the relationship of TDP-43 pathology with the loss of stathmin-2 (STMN2), an essential protein for axonal growth and maintenance. Comparing genetic, cellular, and neuropathological data from patients with TDP-43 proteinopathies (ALS, ALS-frontotemporal dementia [ALS-FTD], and FTLD-TDP-43 [FTLD-TDP]) with data from patients with non-TDP-related neurodegenerations, they demonstrate a direct relationship between TDP-43 pathology and STMN2 reduction. Loss of the normal transcription suppressor function of TDP-43 allowed transcription of an early termination cryptic axon, resulting in truncated, nonfunctional mRNA. The authors suggest that measurement of truncated STMN2 mRNA could be a biomarker for discerning TDP proteinopathies from other pathologies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050777">Stathmin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Clin Invest. 2020 Nov 2;130(11):6080-6092</RefSource><PMID Version="1">32790644</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050777" MajorTopicYN="N">Stathmin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="Y">TDP-43 Proteinopathies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of interest:</b> The author receives funding for clinical trials from Biogen and Genentech.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>19</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33074248</ArticleId><ArticleId IdType="pmc">PMC7598070</ArticleId><ArticleId IdType="doi">10.1172/JCI142854</ArticleId><ArticleId IdType="pii">142854</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kwong LK, Neumann M, Sampathu DM, Lee VM, Trojanowski JQ. TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol. 2007;114(1):63&#x2013;70. doi: 10.1007/s00401-007-0226-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0226-5</ArticleId><ArticleId IdType="pubmed">17492294</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem. 2009;284(30):20329&#x2013;20339. doi: 10.1074/jbc.M109.010264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.010264</ArticleId><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodner RA, et al. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington&#x2019;s and Parkinson&#x2019;s diseases. Proc Natl Acad Sci U S A. 2006;103(11):4246&#x2013;4251. doi: 10.1073/pnas.0511256103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0511256103</ArticleId><ArticleId IdType="pmc">PMC1449678</ArticleId><ArticleId IdType="pubmed">16537516</ArticleId></ArticleIdList></Reference><Reference><Citation>Brotherton TE, Li Y, Glass JD. Cellular toxicity of mutant SOD1 protein is linked to an easily soluble, non-aggregated form in vitro. Neurobiol Dis. 2013;49:49&#x2013;56. doi: 10.1016/j.nbd.2012.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.08.010</ArticleId><ArticleId IdType="pmc">PMC3549044</ArticleId><ArticleId IdType="pubmed">22926189</ArticleId></ArticleIdList></Reference><Reference><Citation>Witan H, Kern A, Koziollek-Drechsler I, Wade R, Behl C, Clement AM. Heterodimer formation of wild-type and amyotrophic lateral sclerosis-causing mutant Cu/Zn-superoxide dismutase induces toxicity independent of protein aggregation. Hum Mol Genet. 2008;17(10):1373&#x2013;1385. doi: 10.1093/hmg/ddn025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddn025</ArticleId><ArticleId IdType="pubmed">18211954</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Petrucelli L. Rodent models of TDP-43 proteinopathy: investigating the mechanisms of TDP-43-mediated neurodegeneration. J Mol Neurosci. 2011;45(3):486&#x2013;499. doi: 10.1007/s12031-011-9610-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-011-9610-7</ArticleId><ArticleId IdType="pmc">PMC3207125</ArticleId><ArticleId IdType="pubmed">21811811</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest. 2011;121(2):726&#x2013;738. doi: 10.1172/JCI44867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI44867</ArticleId><ArticleId IdType="pmc">PMC3026736</ArticleId><ArticleId IdType="pubmed">21206091</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Baloh RH. TDP-43-based animal models of neurodegeneration: new insights into ALS pathology and pathophysiology. Neurodegener Dis. 2011;8(4):262&#x2013;274. doi: 10.1159/000321547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000321547</ArticleId><ArticleId IdType="pmc">PMC3214943</ArticleId><ArticleId IdType="pubmed">21124004</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YR, King OD, Shorter J, Gitler AD. Stress granules as crucibles of ALS pathogenesis. J Cell Biol. 2013;201(3):361&#x2013;372. doi: 10.1083/jcb.201302044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201302044</ArticleId><ArticleId IdType="pmc">PMC3639398</ArticleId><ArticleId IdType="pubmed">23629963</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544(7650):367&#x2013;371. doi: 10.1038/nature22038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Brindisi A, Pagani F, Baralle FE. Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: a functional link with disease penetrance. Am J Hum Genet. 2004;74(6):1322&#x2013;1325. doi: 10.1086/420978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/420978</ArticleId><ArticleId IdType="pmc">PMC1182100</ArticleId><ArticleId IdType="pubmed">15195661</ArticleId></ArticleIdList></Reference><Reference><Citation>Donde A, et al. Splicing repression is a major function of TDP-43 in motor neurons. Acta Neuropathol. 2019;138(5):813&#x2013;826. doi: 10.1007/s00401-019-02042-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02042-8</ArticleId><ArticleId IdType="pmc">PMC6802294</ArticleId><ArticleId IdType="pubmed">31332509</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349(6248):650&#x2013;655. doi: 10.1126/science.aab0983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab0983</ArticleId><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22(2):167&#x2013;179. doi: 10.1038/s41593-018-0300-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22(2):180&#x2013;190. doi: 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Liedtke W, Leman EE, Fyffe RE, Raine CS, Schubart UK. Stathmin-deficient mice develop an age-dependent axonopathy of the central and peripheral nervous systems. Am J Pathol. 2002;160(2):469&#x2013;480. doi: 10.1016/S0002-9440(10)64866-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64866-3</ArticleId><ArticleId IdType="pmc">PMC1850667</ArticleId><ArticleId IdType="pubmed">11839567</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J Clin Invest. 2020;130(11):6080&#x2013;6092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598060</ArticleId><ArticleId IdType="pubmed">32790644</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci U S A. 2013;110(8):E736&#x2013;E745. doi: 10.1073/pnas.1222809110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222809110</ArticleId><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Akiyama T, Warita H, Aoki M. Omics approach to axonal dysfunction of motor neurons in amyotrophic lateral sclerosis (ALS) Front Neurosci. 2020;14:194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7109447</ArticleId><ArticleId IdType="pubmed">32269505</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan JE, Lytle NK, Zuniga A, Goldstein LS. The microtubule regulatory protein stathmin is required to maintain the integrity of axonal microtubules in Drosophila. PLoS ONE. 2013;8(6):e68324. doi: 10.1371/journal.pone.0068324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0068324</ArticleId><ArticleId IdType="pmc">PMC3694009</ArticleId><ArticleId IdType="pubmed">23840848</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadon-Nachum M, Melamed E, Offen D. The &#x201c;dying-back&#x201d; phenomenon of motor neurons in ALS. J Mol Neurosci. 2011;43(3):470&#x2013;477. doi: 10.1007/s12031-010-9467-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-010-9467-1</ArticleId><ArticleId IdType="pubmed">21057983</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185(2):232&#x2013;240. doi: 10.1016/j.expneurol.2003.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer-Hayes LR, Brotherton T, Glass JD. Axonal degeneration in the peripheral nervous system: implications for the pathogenesis of amyotrophic lateral sclerosis. Exp Neurol. 2013;246:6&#x2013;13. doi: 10.1016/j.expneurol.2013.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2013.05.001</ArticleId><ArticleId IdType="pubmed">23664960</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass JD. The ultimate question: why do axons degenerate? A tribute to the work and mentorship of John W. Griffin, MD. J Peripher Nerv Syst. 2012;17 Suppl 3:24&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">23279428</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterloh JM, et al. dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science. 2012;337(6093):481&#x2013;484. doi: 10.1126/science.1223899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1223899</ArticleId><ArticleId IdType="pmc">PMC5225956</ArticleId><ArticleId IdType="pubmed">22678360</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M, et al. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS ONE. 2007;2(8):e689. doi: 10.1371/journal.pone.0000689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0000689</ArticleId><ArticleId IdType="pmc">PMC1925150</ArticleId><ArticleId IdType="pubmed">17668067</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould TW, et al. Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J Neurosci. 2006;26(34):8774&#x2013;8786. doi: 10.1523/JNEUROSCI.2315-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2315-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674380</ArticleId><ArticleId IdType="pubmed">16928866</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>